BioStock: Cereno Scientific delays start of phase II trial
Today, Cereno Scientific announced that they have postponed the start of their phase II trial for the main compound CS1 in thrombosis prevention. For the time being, the start has been moved from mid 2020 to late 2020, but the company is open to the need for further adjustments depending on the development of the ongoing coronavirus outbreak.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se